Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration

Brian A Ference, Christopher P Cannon, Ulf Landmesser, Thomas F Lüscher, Kausik K Ray, Alberico Luigi Catapano

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalEuropean Heart Journal
Publication statusE-pub ahead of print - Aug 14 2017

Cite this